Dualyx
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $40M
Overview
Creates bispecific antibody therapies that precisely modulate the immune system to treat autoimmune diseases without broad suppression.
ImmunologyAutoimmune Disease
Technology Platform
A bispecific antibody platform engineered to co-engage two immune cell surface targets, enabling selective modulation of pathogenic T cells in autoimmune diseases.
Funding History
1Total raised:$40M
PIPE$40M
Opportunities
Potential to redefine treatment standards in autoimmune diseases by offering therapies with best-in-class efficacy and safety profiles.
Risk Factors
High biological and technical risk associated with pioneering a novel, unproven mechanism of action in the complex human immune system.
Competitive Landscape
Enters a crowded autoimmune market but differentiates through a novel bispecific mechanism aimed at achieving precision immune modulation without broad suppression.